Wealth Watch Advisors INC Makes New $186,000 Investment in Boston Scientific Corporation $BSX

Wealth Watch Advisors INC bought a new stake in shares of Boston Scientific Corporation (NYSE:BSX) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 1,734 shares of the medical equipment provider’s stock, valued at approximately $186,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Brighton Jones LLC lifted its position in Boston Scientific by 0.8% during the 4th quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock valued at $2,445,000 after acquiring an additional 226 shares during the period. GAMMA Investing LLC grew its holdings in Boston Scientific by 17.2% in the first quarter. GAMMA Investing LLC now owns 25,554 shares of the medical equipment provider’s stock worth $2,578,000 after purchasing an additional 3,745 shares during the period. Golden State Wealth Management LLC increased its stake in shares of Boston Scientific by 37.0% during the first quarter. Golden State Wealth Management LLC now owns 1,674 shares of the medical equipment provider’s stock valued at $169,000 after purchasing an additional 452 shares in the last quarter. Perigon Wealth Management LLC lifted its holdings in shares of Boston Scientific by 7.9% during the first quarter. Perigon Wealth Management LLC now owns 13,532 shares of the medical equipment provider’s stock valued at $1,365,000 after purchasing an additional 996 shares during the last quarter. Finally, Diversified Trust Co lifted its holdings in shares of Boston Scientific by 15.9% during the first quarter. Diversified Trust Co now owns 5,236 shares of the medical equipment provider’s stock valued at $528,000 after purchasing an additional 718 shares during the last quarter. 89.07% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

BSX has been the topic of several recent research reports. Jefferies Financial Group restated a “hold” rating on shares of Boston Scientific in a research note on Monday, July 21st. Wells Fargo & Company boosted their target price on Boston Scientific from $124.00 to $125.00 and gave the stock an “overweight” rating in a report on Thursday. UBS Group raised their price target on Boston Scientific from $135.00 to $140.00 and gave the company a “buy” rating in a report on Thursday. Truist Financial lifted their price target on Boston Scientific from $129.00 to $130.00 and gave the stock a “buy” rating in a research report on Thursday. Finally, Raymond James Financial upped their price target on shares of Boston Scientific from $121.00 to $124.00 and gave the stock a “strong-buy” rating in a research note on Thursday, July 24th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $123.77.

Boston Scientific Stock Down 1.3%

BSX stock opened at $101.08 on Monday. The stock has a market capitalization of $149.78 billion, a P/E ratio of 54.06, a P/E/G ratio of 2.04 and a beta of 0.61. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.37 and a quick ratio of 0.82. Boston Scientific Corporation has a 1-year low of $80.64 and a 1-year high of $109.50. The business has a fifty day moving average price of $101.14 and a 200-day moving average price of $102.12.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, October 22nd. The medical equipment provider reported $0.75 EPS for the quarter, beating the consensus estimate of $0.71 by $0.04. Boston Scientific had a return on equity of 19.74% and a net margin of 14.43%.The company had revenue of $5.07 billion for the quarter, compared to analysts’ expectations of $4.97 billion. During the same period last year, the firm posted $0.63 earnings per share. Boston Scientific’s revenue was up 20.3% compared to the same quarter last year. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS. Equities analysts forecast that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Insider Transactions at Boston Scientific

In other Boston Scientific news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the business’s stock in a transaction on Wednesday, October 1st. The shares were sold at an average price of $98.47, for a total transaction of $4,923,500.00. Following the completion of the sale, the executive vice president directly owned 178,342 shares in the company, valued at approximately $17,561,336.74. The trade was a 21.90% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Yoshiaki Fujimori sold 2,901 shares of the stock in a transaction on Tuesday, July 29th. The shares were sold at an average price of $106.99, for a total value of $310,377.99. Following the transaction, the director directly owned 2,081 shares in the company, valued at $222,646.19. The trade was a 58.23% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 170,214 shares of company stock worth $17,548,337 over the last three months. 0.50% of the stock is currently owned by company insiders.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.